Tech Company Financing Transactions
Thryv Therapeutics Funding Round
Thryv Therapeutics closed a $30 million Series B funding round on 11/3/2026. Investors included adMare BioInnovations, Alexandria Venture Investments and Amplitude Ventures.
Transaction Overview
Company Name
Announced On
11/3/2026
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Proceeds Purpose
Thryv Therapeutics will use the $30 million Series B financing to advance its lead drug candidate, THRV-1268, into the ASPIRE-HF Phase 2a clinical study for patients suffering from heart failure with reduced ejection fraction (HFrEF) and prolonged QTc intervals. The funding will support clinical trial operations, patient enrollment, safety and efficacy assessments, pharmacokinetic evaluations, and the analysis of cardiac function and heart failure risk biomarkers. The company will also leverage InClin's clinical research and operational expertise to establish and expand clinical operations in Australia, with the ASPIRE-HF study expected to begin enrolling patients in early 2027.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
999 Boulevard De Maisonneuve Ouest 1250
Montreal, Quebec, H3A 3L4
CA
Montreal, Quebec, H3A 3L4
CA
Phone
Website
Email Address
Overview
Thryv Therapeutics is a clinical-stage biotechnology company developing precision medicines for inherited cardiac arrhythmias, cardiometabolic diseases and cardiomyopathies. The company develops selective SGK1 inhibitors, including its lead drug candidate THRV-1268, which is being evaluated in clinical trials.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Truex
Chief Medical Officer
Amy Sehnert
Browse more venture capital transactions:
Prev: 11/3/2026: Apolarion venture capital transaction
Next: 11/3/2026: Hoxton Wealth venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs